# Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer

> **NCT00002679** · PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 89 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** paclitaxel
- **DRUG:** tamoxifen citrate
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00002679
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-02
- **Primary completion:** 2002-01
- **Final completion:** 2002-01
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2009-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002679, "Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00002679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*